四川医学
四川醫學
사천의학
SICHUAN MEDICAL JOURNAL
2014年
9期
1139-1142,1143
,共5页
支气管哮喘%糖皮质激素%儿童%Meta分析
支氣管哮喘%糖皮質激素%兒童%Meta分析
지기관효천%당피질격소%인동%Meta분석
asthma%glucocorticoids%children%meta-analysis
目的:采用Meta分析系统评价支气管哮喘儿童吸入糖皮质激素( ICS)的安全性。方法检索Cochrane随机对照试验中心、MEDLINE、CNKI等数据库中有关采用ICS治疗儿童支气管哮喘的随机对照研究(1990.1-2014.2),并用RevMan4.2软件进行统计分析。结果共纳入符合条件的文献15篇,累计试验组病例1822例、对照1492例。数据合并结果显示,无论治疗时间长短,患儿骨密度无明显降低(WMD=0.01,95%CI:-0.03~0.05,P=0.59);成年后的身高与对照组比较差异无统计学意义(WMD=-0.07,95%CI:-0.21~0.07,P=0.33)。短期治疗结果表明,患儿身高增长率、足生长率均有所降低(WMD=-0.58,95%CI:-1.03~-0.13,P=0.01)、(WMD=-0.11,95%CI:-0.21~-0.01,P=0.03)。中长期治疗时,患儿身高增长率与对照组比较差异无统计学意义(WMD=-0.25,95%CI:-1.67~1.18,P=0.73)。结论本研究初步提示,ICS治疗患儿骨密度无降低;短期ICS治疗对患儿身高发育有一定影响,但随着治疗时间的延长该现象会消失,且不会累及患儿成年后的身高。
目的:採用Meta分析繫統評價支氣管哮喘兒童吸入糖皮質激素( ICS)的安全性。方法檢索Cochrane隨機對照試驗中心、MEDLINE、CNKI等數據庫中有關採用ICS治療兒童支氣管哮喘的隨機對照研究(1990.1-2014.2),併用RevMan4.2軟件進行統計分析。結果共納入符閤條件的文獻15篇,纍計試驗組病例1822例、對照1492例。數據閤併結果顯示,無論治療時間長短,患兒骨密度無明顯降低(WMD=0.01,95%CI:-0.03~0.05,P=0.59);成年後的身高與對照組比較差異無統計學意義(WMD=-0.07,95%CI:-0.21~0.07,P=0.33)。短期治療結果錶明,患兒身高增長率、足生長率均有所降低(WMD=-0.58,95%CI:-1.03~-0.13,P=0.01)、(WMD=-0.11,95%CI:-0.21~-0.01,P=0.03)。中長期治療時,患兒身高增長率與對照組比較差異無統計學意義(WMD=-0.25,95%CI:-1.67~1.18,P=0.73)。結論本研究初步提示,ICS治療患兒骨密度無降低;短期ICS治療對患兒身高髮育有一定影響,但隨著治療時間的延長該現象會消失,且不會纍及患兒成年後的身高。
목적:채용Meta분석계통평개지기관효천인동흡입당피질격소( ICS)적안전성。방법검색Cochrane수궤대조시험중심、MEDLINE、CNKI등수거고중유관채용ICS치료인동지기관효천적수궤대조연구(1990.1-2014.2),병용RevMan4.2연건진행통계분석。결과공납입부합조건적문헌15편,루계시험조병례1822례、대조1492례。수거합병결과현시,무론치료시간장단,환인골밀도무명현강저(WMD=0.01,95%CI:-0.03~0.05,P=0.59);성년후적신고여대조조비교차이무통계학의의(WMD=-0.07,95%CI:-0.21~0.07,P=0.33)。단기치료결과표명,환인신고증장솔、족생장솔균유소강저(WMD=-0.58,95%CI:-1.03~-0.13,P=0.01)、(WMD=-0.11,95%CI:-0.21~-0.01,P=0.03)。중장기치료시,환인신고증장솔여대조조비교차이무통계학의의(WMD=-0.25,95%CI:-1.67~1.18,P=0.73)。결론본연구초보제시,ICS치료환인골밀도무강저;단기ICS치료대환인신고발육유일정영향,단수착치료시간적연장해현상회소실,차불회루급환인성년후적신고。
Objective To evaluate the safety of inhaled glucocorticoids( ICS) therapy for children asthma. Methods The Cochrane Library,MEDLINE and CNKI databases(1990. 1~2014. 2) were searched for randomized controlled trials involving the safety of ICS therapy for children asthma. Revman 4. 2 software was used for Meta-analysis. Results Fifteen trials were selected in this study,including 1822 ICS treatment cases and 1492 controls. The combined data firstly showed no statistically significant differences were found in both mean bone mineral density and mean adult height between any of the treatment groups at any time (WMD=0. 01,95%CI:-0. 03~0. 05,P=0. 59)、(WMD= -0. 07,95%CI:-0. 21~0. 07,P=0. 33). The height velocity and lower-leg velocity of the ICS group were lower than those of the placebo groups for short term(WMD= -0. 58,95%CI:-1. 03~-0. 13,P=0. 01)、(WMD= -0. 11,95%CI:-0. 21~ -0. 01,P=0. 03). However,there were no statistically significant differ-ences in height velocity between cases for long term treatment and controls(WMD= -0. 25,95%CI:-1. 67~1. 18,P=0. 73). Conclusion The present study suggested that there is some bad influence in height growth of asthma children treated with ICS, but with time prolonged,it will disappear and has not influence on the adult height.